- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02311959
Therapeutic Nipple Sparing Mastectomy. (MAPAM-01)
Therapeutic Nipple Areola Skin-sparing Mastectomy.
This is a phase III, multicentric, single arm study with a sequential design using the exact conditional Poisson test.
The primary objective of this prospective study is to evaluate whether selected breast carcinoma patients could be treated with nipple sparing mastectomy (NSM) with an acceptable low local recurrence rates.
450 patients will be included over a period of 4 years and will be followed for a 5 years period (twice a year).
All patients must have a complete preoperative evaluation (bilateral mammography, bilateral breast ultrasonography +/- MRI), and a histopathological diagnostic proof of carcinoma (invasive or in situ, all histopathological types, first treatment or relapse).
The study procedure is represented by nipple areola skin-sparing mastectomy followed by immediate breast reconstruction.
After surgery, early and late complications, including specific complications (suffering of the nipple-areolar complexe and suffering of the skin flaps), will be evaluate.
An esthetic evaluation (by patient and clinician) and a quality of life evaluation will be realized throughout the study.
A complementary study, prospective, non-interventional, will be proposed to patients who will benefit from the same surgical technique (NSM) followed by immediate reconstruction, but in the context of preventive surgery (prophylactic surgery for patients mutated or high genetic risk). The aim of this complementary study, which will include a maximum of 60 patients, is to evaluate associated morbidity in prophylactic NSM.
Data will be collected over a 3 months period after surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Blois, France, 41000
- Centre Hospitalier de Blois
-
Bordeaux, France, 33076
- Institut Bergonie
-
Chambray-lès-Tours, France, 37170
- Pole Sante Leonard de Vinci
-
Dijon, France, 21079
- Centre Georges François Leclerc
-
Guilherand-Granges, France, 07500
- Hôpital privé Drôme Ardèche
-
La Rochelle, France, 17000
- Clinique du Mail
-
La Tronche, France, 38700
- Centre Hospitalier Universitaire Grenoble Alpes
-
Lambres-lez-Douai, France, 59552
- Clinique Saint Ame
-
Levallois-perret, France, 92300
- Hopital de Levallois-Perret
-
Lille, France, 59000
- Centre Oscar Lambret
-
Lyon, France, 69008
- Centre Leon Berard
-
Lyon, France, 69317
- Hôpital de La Croix Rousse
-
Marseille, France, 13273
- Institut Paoli Calmettes
-
Montpellier, France, 34295
- Centre Hospitalier Universitaire de Montpellier
-
Montpellier, France, 34298
- Institut Du Cancer de Montpellier
-
Montpellier, France, 34070
- Clinique Clementville
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Paris, France, 75015
- Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris
-
Paris, France, 75020
- AP-HP - Hopital Tenon
-
Pierre Benite, France, 69495
- CHRU Lyon Sud
-
Poitiers, France, 86 000
- Centre Hospitalier de Poitiers
-
Rennes, France, 35042
- Centre Eugène Marquis
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Rouen, France, 76175
- Clinique Mathilde
-
Saint-Etienne, France, 42013
- Clinique Mutualiste Chirurgicale
-
Saint-Grégoire, France, 35760
- Etablissement Rennais du Sein - CHP St Grégoire
-
Saint-Herblain, France, 44805
- Institut de Cancérologie de l'Ouest - Site René Gauducheau
-
Saint-cloud, France, 92210
- Hôpital René Huguenin
-
Saint-Étienne, France, 42100
- Hôpital privé de la Loire
-
Toulouse, France, 31059
- Institut Claudius Regaud
-
Toulouse, France, 31077
- Clinique Saint Jean
-
Vandoeuvre-Les-Nancy, France, 54519
- Institut de Cancerologie de Lorraine
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient with invasive breast carcinoma stage T1 or T2 and / or in situ (any histological type) proved on histopathological diagnosis.
- Patient with an indication of total mastectomy.
- Patient without preoperative indication of adjuvant radiotherapy according to regional and / or national guidelines.
- Disease located more than 2 cm from the nipple after complete clinical and radiologic breast evaluation (mammography, ultrasound +/- MRI).
- Initial breast cancer or recurrence.
- Patient wishing to receive immediate breast reconstruction.
- WHO performance < or = 2.
- Patient older than 40 years.
- For patients of childbearing age, use an effective contraceptive methods for the duration of the study.
- For patients of childbearing potential, negative pregnancy test available before inclusion.
- Patient affiliated to a social health insurance in France.
- Patient who signed informed consent before enrollment in the study and before any specific procedure for the study.
Exclusion Criteria :
- Positive node on physical examination or proved by cytology.
- Combination of 2 predictive factors of postoperative radiotherapy : macroscopic multifocal, grade 2 or 3, vascular emboli, overexpressed HER2 (human epidermal growth factor receptor-2), triple negative (Estrogen Receptor, Progesterone Receptor and HER2 negative).
- Neoadjuvant treatment for the current disease.
- Patient with bilateral breast cancer.
- Paget disease.
- T3 or T4 carcinoma.
- Metastatic breast cancer (disease staging realized according to national or regional guidelines).
- Breast hypertrophy requiring a nipple support flap.
- Nursing or pregnant woman.
- Patient participating in any other interventional clinical study.
- Any psychological, familial, geographic or social situation not to comply with medical monitoring and/or procedures in the study protocol.
- Patient protected by law.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Invasive or in situ breast carcinoma.
|
Standardized surgical procedure by :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local recurrence rate.
Time Frame: 9 years.
|
Annual incidence of local recurrence defined by the number of local recurrences (skin, thoracic wall and nipple) among the patient years of follow-up..
|
9 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early and late complications
Time Frame: 9 years.
|
Early and late complications will be evaluated using NCI toxicity scale version 4.0.
|
9 years.
|
Disease free Survival.
Time Frame: 9 years.
|
Disease-free survival is the period between the date of origin and date of the first event as defined below, or date of latest news (Censored Data). The events included in the definition of disease-free survival are local recurrence, lymph node metastases, contralateral locations, distant metastases, second breast cancer and death from any causes. |
9 years.
|
Metastasis Free Survival.
Time Frame: 9 years.
|
Metastasis free survival is defined as the time from inclusion until the date of metastasis recurrence or the date of the latest news (Censored data).
|
9 years.
|
Overall Survival.
Time Frame: 9 years
|
Overall survival is defined as the time from inclusion until the date of death or the date of the latest news (Censored data).
|
9 years
|
Aesthetic evaluation.
Time Frame: 9 years.
|
The aesthetic evaluation will be realized by both the surgeon and the patient using to the Licket scale.
|
9 years.
|
Quality of life.
Time Frame: 9 years.
|
The quality of life will be evaluated according to the Breast-Q questionnaire.
|
9 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Eva JOUVE, Md., IUCT-O
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 14 SEIN 10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Nipple sparing mastectomy
-
Severance HospitalSamsung Medical Center; Asan Medical Center; Kyungpook National University Chilgok...RecruitingBreast Neoplasms | Benign Breast Disease | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation | Germline Mutation AbnormalityKorea, Republic of
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalRecruiting
-
Severance HospitalSamsung Medical Center; Changhua Christian Hospital; European Institute of OncologyCompletedRecurrence | Postoperative Complications | Breast Cancer | Breast Neoplasms | Surgery | Surgery--Complications | BRCA1 Mutation | BRCA2 MutationKorea, Republic of
-
Yonsei UniversityRecruitingBreast Cancer Patients in Stage 0-3A in Preoperative EvaluationKorea, Republic of
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalUnknownBreast Cancer FemaleTaiwan, Korea, Republic of, Italy
-
Intuitive SurgicalRecruiting
-
Wake Forest University Health SciencesCompletedBreast Cancer | Breast Reconstruction | CosmesisUnited States
-
Intuitive SurgicalTerminatedProphylactic Nipple Sparing Mastectomy (NSM)Italy, France
-
Intuitive SurgicalRecruitingNipple Sparing MastectomyUnited States
-
Alexandria UniversityCompleted